The use of prostate-specific antigen kinetics to stratify risk in prostate cancer.
Risk assessment is critical to providing appropriate counseling and treatment for patients diagnosed with prostate cancer. The three classic clinical parameters to determine risk have been clinical stage, biopsy grade, and prostate-specific antigen (PSA) level. More recently, the importance of PSA kinetics has been realized in the pretreatment and serologic relapse settings. This article reviews the use of PSA velocity and PSA doubling time in several clinical scenarios.
Presti
Joseph
J
Director of Urologic Oncology, Stanford University School of Medicine, 875 Blake Wilbur Drive, Room CC-2217, Stanford, CA 94305, USA.